J Clin Rheumatol 2021 Apr 9. Epub 2021 Apr 9.
From the Department of Pediatric Rheumatology, Ankara Children's Hospital, University of Health Sciences Pediatric Intensive Care Unit, Ankara Children's Hospital, Ankara Yildirim Beyazit University Department of Pediatric Intensive Care, Ankara Children's Hospital, University of Health Sciences Department of Pediatric Rheumatology, Faculty of Medicine, Selçuk University Department of Pediatric Cardiology, Ankara Children's Hospital, University of Health Sciences Department of Pediatric Infectious Diseases, Ankara Children's Hospital, Ankara Yildirim Beyazit University Department of Pediatric Hematology, Ankara Children's Hospital, University of Health Sciences Department of Pediatric Surgery, Ankara Children's Hospital, Ankara Yildirim Beyazit University, Ankara, Turkey.
Objectives: The aims of this study were to evaluate the role of biological agents in the treatment of severe multisystem inflammatory syndrome in children (MIS-C) and to assess the current application, outcomes, and adverse effects in patients who are followed up in a pediatric intensive care unit (PICU).
Patients And Methods: This observational, descriptive, medical records review study was performed on patients with MIS-C admitted to the PICU between September 1 and November 1, 2020. Through medical records review, we confirmed that patients were positive for current or recent SARS-CoV-2 infection or for COVID-19 exposure history within the 4 weeks before the onset of symptoms. Read More